EVŌQ Nano Secures $10 Million Funding for Innovative Nanoparticle Technology Across Three Industries!

EVŌQ Nano, a pioneering nanoscience company specializing in the engineering of novel nanoparticles, has successfully raised an impressive $10 million in a recent funding round. The company leverages its multi-patented, high-volume laser nanofabrication process to create uniform, sub-10 nm nanoparticles with distinct surface chemistry, which opens doors to significant advancements in various industries, including life sciences, materials, and textiles. This critical funding will be instrumental in propelling EVŌQ Nano’s innovative projects forward. Notably, EVŌQ Bio is progressing with EVQ-218, a groundbreaking inhaled therapeutic aimed at treating pulmonary bacterial infections in cystic fibrosis patients, following a successful pre-Investigational New Drug meeting with the FDA—now setting its sights on Phase I clinical trials. Meanwhile, EVŌQ MedTech is on the frontier of integrating antimicrobial features into medical devices, striving to reduce healthcare-associated infections (HAIs) that impact over a million hospital patients annually. Lastly, FUZE Technologies is carving a niche in the textile and hospitality sectors with its EPA-approved antimicrobial technology that boasts a chemical-free, non-toxic profile, appealing to eco-conscious brands like Nike, Adidas, and major hotel chains. With this latest funding, EVŌQ Nano is positioned to expand its innovative capabilities, paving the way for transformative solutions that enhance health, safety, and sustainability across multiple sectors.